EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Age Does Not Affect Respiratory Characteristics in Children With Prader‐Willi Syndrome Before and After Growth Hormone Therapy

Michelle Ip, Sze Lut Cheng, Okkes R Patoglu, Georgina Plunkett iD, Lauren C Nisbet, Gillian M Nixon, Margot J Davey, Rosemary S C Horne

Acta Paediatrica · 2026

DOI: 10.1111/apa.70459 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Paediatrica, 2026. Verfasst von Michelle Ip und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatrics, Monash University, Melbourne, Australia. Hauptthemen laut MEDLINE: Prader-Willi Syndrome, Sleep Apnea, Obstructive, Human Growth Hormone, Sleep Apnea, Central. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Children with Prader‐Willi syndrome (PWS) are at increased risk of both central (CSA) and obstructive sleep apnoea (OSA). Studies examining the effects of growth hormone have focused on older children; however, therapy is often initiated before the age of 2 years. We determined the effects of age on (1) the number of children diagnosed with OSA and CSA; (2) the sleep and respiratory characteristics and (3) the effects of growth hormone on OSA and CSA.

Methods

Retrospective review of children with PWS who underwent polysomnography pre‐ and post‐growth hormone between January 2011 and June 2024.

Results

Fifty‐six children (35 < 2 years; 21 ≥ 2 years) pre‐growth hormone; 28 children < 2 years and 15 children ≥ 2 years after growth hormone. Pre‐growth hormone, children ≥ 2 years had more severe OSA than children < 2 years ( p < 0.05). There was no difference between age groups for CSA. Post‐growth hormone, 21% of children < 2 years and 20% of children ≥ 2 years developed OSA. CSA resolved post‐growth hormone in 21% of children < 2 years and 6% of children ≥ 2 years, whilst CSA developed in 11% and 13%, respectively.

Conclusion

Our study highlights that very young children do not appear to be at higher risk of development of OSA or CSA when treated with growth hormone.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prader-Willi SyndromeSleep Apnea, ObstructiveHuman Growth HormoneSleep Apnea, CentralHumansChild, PreschoolRetrospective StudiesPolysomnographyFemaleMaleAge FactorsChildInfant

Stichwörter der Autor:innen

Prader‐Willi syndromecentral sleep apnoeagrowth hormoneobstructive sleep apnoeasleep

Substanzen

Human Growth Hormone

Autor:innen und Institutionen

  • Department of Paediatrics, Monash University, Melbourne, Australia.
  • Melbourne Children's Sleep Centre, Monash Children's Hospital, Melbourne, Australia.

ORCID-Profile: Georgina Plunkett

Förderung

  • National Health and Medical Research Council

Zitieren

APA

Ip, M., Cheng, S. L., Patoglu, O. R., Plunkett, G., Nisbet, L. C., Nixon, G. M., Davey, M. J., & Horne, R. S. C. (2026). Age Does Not Affect Respiratory Characteristics in Children With Prader‐Willi Syndrome Before and After Growth Hormone Therapy. Acta Paediatrica. https://doi.org/10.1111/apa.70459

Vancouver

Ip M, Cheng SL, Patoglu OR, Plunkett G, Nisbet LC, Nixon GM, et al. Age Does Not Affect Respiratory Characteristics in Children With Prader‐Willi Syndrome Before and After Growth Hormone Therapy. Acta Paediatrica. 2026. doi:10.1111/apa.70459

BibTeX
@article{Ip2026,
  author = {Ip, Michelle and Cheng, Sze Lut and Patoglu, Okkes R and Plunkett, Georgina and Nisbet, Lauren C and Nixon, Gillian M and Davey, Margot J and Horne, Rosemary S C},
  title = {Age Does Not Affect Respiratory Characteristics in Children With Prader‐Willi Syndrome Before and After Growth Hormone Therapy},
  journal = {Acta Paediatrica},
  year = {2026},
  doi = {10.1111/apa.70459}
}
Kostenlos starten →